Cargando…

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors

Detalles Bibliográficos
Autores principales:	Einama, Takahiro, Kawamata, Futoshi, Kamachi, Hirofumi, Nishihara, Hiroshi, Homma, Shigenori, Matsuzawa, Fumihiko, Mizukami, Tatsuzo, Konishi, Yuji, Kamiyama, Toshiya, Yamamoto, Junji, Taketomi, Akinobu, Todo, Satoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652283/ https://www.ncbi.nlm.nih.gov/pubmed/28965877 http://dx.doi.org/10.1016/j.ebiom.2017.09.033

Ejemplares similares

The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model
por: Mizukami, Tatsuzo, et al.
Publicado: (2018)

Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells
por: Matsuzawa, Fumihiko, et al.
Publicado: (2021)

Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms
por: EINAMA, TAKAHIRO, et al.
Publicado: (2015)

Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
por: Einama, T, et al.
Publicado: (2012)

Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer
por: Mizukami, Tatsuzo, et al.
Publicado: (2018)

Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy
por: Mizukami, Tatsuzo, et al.
Publicado: (2014)

Significance of mesothelin expression in preoperative endoscopic biopsy specimens for colorectal cancer prognosis
por: Shiraishi, Takehiro, et al.
Publicado: (2020)

Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis
por: Kakimoto, Soichiro, et al.
Publicado: (2021)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma
por: Kamiyama, Toshiya, et al.
Publicado: (2012)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Membrane mesothelin expression positivity is associated with poor clinical outcome of luminal-type breast cancer
por: Suzuki, Takafumi, et al.
Publicado: (2020)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium
por: Wakayama, Kenji, et al.
Publicado: (2013)

L-Carnitine supplementation reduces the general fatigue of cancer patients during chemotherapy
por: Matsui, Hiroki, et al.
Publicado: (2018)

Near infrared photoimmunotherapy with an anti-mesothelin antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2016)

The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
por: Hilliard, Tyvette S.
Publicado: (2018)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
por: Faust, Joshua R., et al.
Publicado: (2022)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells
por: Lazzerini, Lea, et al.
Publicado: (2020)

The Role of Mesothelin in Activation of Portal Fibroblasts in Cholestatic Liver Injury
por: Nishio, Takahiro, et al.
Publicado: (2022)

Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin
por: Lurie, Eugene, et al.
Publicado: (2020)

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany
por: Rihs, Hans-Peter, et al.
Publicado: (2022)

Characterization of human mesothelin transcripts in ovarian and pancreatic cancer
por: Muminova, Zhanat E, et al.
Publicado: (2004)

Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma
por: Yu, Liping, et al.
Publicado: (2010)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Preoperative Serum Levels of Mesothelin in Patients with Colon Cancer
por: Bostancı, Özgür, et al.
Publicado: (2014)

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
por: Zhao, Xiao-Yan, et al.
Publicado: (2016)

Amatuximab and novel agents targeting mesothelin for solid tumors
por: Baldo, Paolo, et al.
Publicado: (2017)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Multiple proteases are involved in mesothelin shedding by cancer cells
por: Liu, Xiufen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u5he68kra9j08ln7iam0k3c9ak